These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 38369433)

  • 1. Comparison of tumor response and outcomes of patients with hepatocellular carcinoma after multimodal treatment including immune checkpoint inhibitors - a systematic review and meta-analysis.
    Dawood ZS; Brown ZJ; Alaimo L; Lima HA; Shaikh C; Katayama ES; Munir MM; Moazzam Z; Endo Y; Woldesenbet S; Pawlik TM
    HPB (Oxford); 2024 May; 26(5):618-629. PubMed ID: 38369433
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transarterial Chemoembolization Combined with Tyrosine Kinase Inhibitors Plus Immune Checkpoint Inhibitors Versus Tyrosine Kinase Inhibitors Plus Immune Checkpoint Inhibitors in Unresectable Hepatocellular Carcinoma with First- or Lower-Order Portal Vein Tumor Thrombosis.
    Zhang JX; Cheng Y; Wei J; Fan WL; Liu J; Zhou CG; Liu S; Shi HB; Chu XY; Zheng WL; Zu QQ
    Cardiovasc Intervent Radiol; 2024 Jun; 47(6):751-761. PubMed ID: 38671322
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of Transarterial Chemoembolization in the Era of Tyrosine Kinase Inhibitor and Immune Checkpoint Inhibitor Combination Therapy for Unresectable Hepatocellular Carcinoma: A Retrospective Propensity Score Matched Analysis.
    Zhang JX; Hua HJ; Cheng Y; Liu S; Shi HB; Zu QQ
    Acad Radiol; 2024 Apr; 31(4):1304-1311. PubMed ID: 37775449
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TACE plus tyrosine kinase inhibitors and immune checkpoint inhibitors versus TACE plus tyrosine kinase inhibitors for the treatment of patients with hepatocellular carcinoma: a meta-analysis and trial sequential analysis.
    Liu J; Wang P; Shang L; Zhang Z; Tian Y; Chen X; Ma Y; Shao H
    Hepatol Int; 2024 Apr; 18(2):595-609. PubMed ID: 37843788
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transarterial chemoembolization combined with molecular targeted agents plus immune checkpoint inhibitors for unresectable hepatocellular carcinoma beyond the up-to-seven criteria: a propensity score-matching analysis.
    Chen W; Yan HT; Zhang JX; Zhou CG; Liu J; Liu S; Shi HB; Cheng Y; Zu QQ
    Ann Med; 2024 Dec; 56(1):2419993. PubMed ID: 39484705
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Significance of Transarterial Chemo(Embolization) Combined With Tyrosine Kinase Inhibitors and Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma in the Era of Systemic Therapy: A Systematic Review.
    Ke Q; Xin F; Fang H; Zeng Y; Wang L; Liu J
    Front Immunol; 2022; 13():913464. PubMed ID: 35677059
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical efficacy of lenvatinib, trans-arterial chemoembolization, and PD-1/L1 inhibitors in advanced hepatocellular carcinoma: a systematic review and network meta-analysis.
    Liang Y; Gan L; Zeng D; Lin L; Xiong Z; Liao F; Wang A
    Clin Transl Oncol; 2024 Oct; 26(10):2652-2664. PubMed ID: 38671328
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Triple combination of HAIC-FO plus tyrosine kinase inhibitors and immune checkpoint inhibitors for advanced hepatocellular carcinoma: A systematic review and meta-analysis.
    Tan Z; Zhang J; Xu L; Wang H; Mao X; Zou R; Wang Q; Han Z; Di Z; Wu D
    PLoS One; 2023; 18(10):e0290644. PubMed ID: 37844117
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and Safety of TACE Combined with a Tyrosine Kinase Inhibitor for the Treatment of TACE-Refractory Hepatocellular Carcinoma: A Retrospective Comparative Study.
    Chen YX; Zhang JX; Zhou CG; Liu J; Liu S; Shi HB; Zu QQ; Cheng Y
    J Gastrointest Cancer; 2024 Jun; 55(2):924-931. PubMed ID: 38470522
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-world efficacy and safety of TACE-HAIC combined with TKIs and PD-1 inhibitors in initially unresectable hepatocellular carcinoma.
    Pang B; Zuo B; Huang L; You X; Liu T; Hao J; Yuan C; Yang C; Yee Lau W; Zhang Y
    Int Immunopharmacol; 2024 Aug; 137():112492. PubMed ID: 38906005
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluating the impact of treatment sequencing on outcomes in hepatocellular carcinoma: a comparative analysis of TACE and systemic therapies.
    Zheng X; Song X; Zhang B; Chen X; Zhang Y; Luo Q; Li Z; Deng Z; Xu R; Peng L; Xie C
    Clin Exp Med; 2024 Oct; 24(1):238. PubMed ID: 39382711
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of drug-eluting bead transarterial chemoembolization (DEB-TACE) combined with tyrosine kinase inhibitors (TKIs) in patients with unresectable hepatocellular carcinoma (uHCC): A systematic review and meta-analysis.
    Ji J; Zhang Z; Hou Z; Qiu G; Mi S; Jin Z; Huang J
    Clin Res Hepatol Gastroenterol; 2024 Apr; 48(4):102313. PubMed ID: 38453011
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systemic conversion therapies for initially unresectable hepatocellular carcinoma: a systematic review and meta-analysis.
    Xu H; Zhang H; Li B; Chen K; Wei Y
    BMC Cancer; 2024 Aug; 24(1):1008. PubMed ID: 39143584
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune checkpoint inhibitors and tyrosine kinase inhibitors in patients with advanced hepatocellular carcinoma: Does the sequence matter?
    Ng KYY; Wong LWJ; Ang AJS; Lee AWX; Tay DSH; Tan JJE; Tan SH; Choo SP; Tai DW; Lee JJX
    Asia Pac J Clin Oncol; 2023 Jun; 19(3):312-319. PubMed ID: 35950298
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparing Safety and Efficacy of TACE + Apatinib in Combination with a PD-1 Inhibitor versus a Non-triple Therapy for Treating Advanced Primary Hepatocellular Carcinoma: A Systematic Review and Meta-analysis.
    Pan D; Liu H; Qu P; Chen X; Ma X; Wang Y; Qin X; Han Z
    J Gastrointestin Liver Dis; 2024 Mar; 33(1):85-93. PubMed ID: 38554419
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transarterial chemoembolization (TACE) plus tyrosine kinase inhibitors versus TACE in patients with hepatocellular carcinoma: a systematic review and meta-analysis.
    Duan R; Gong F; Wang Y; Huang C; Wu J; Hu L; Liu M; Qiu S; Lu L; Lin Y
    World J Surg Oncol; 2023 Mar; 21(1):120. PubMed ID: 37004052
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Effectiveness and Safety of Transarterial Chemoembolization: Hepatic Artery Infusion Chemotherapy Plus Tyrosine Kinase Inhibitors With or Without Programmed Cell Death Protein-1 Inhibitors for Unresectable Hepatocellular Carcinoma-A Retrospective Study.
    Chen Y; Jia L; Li Y; Cui W; Wang J; Zhang C; Bian C; Wang Z; Lin D; Luo T
    Ann Surg Oncol; 2024 Nov; 31(12):7860-7869. PubMed ID: 39090499
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of first-line treatments for advanced hepatocellular carcinoma patients: a systematic review and network meta-analysis.
    Li J; Yang B; Teng Z; Liu Y; Li D; Qu X
    Front Immunol; 2024; 15():1430196. PubMed ID: 39355238
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of apatinib plus immune checkpoint inhibitors and transarterial chemoembolization for the treatment of advanced hepatocellular carcinoma.
    Wu J; Bai X; Yu G; Zhang Q; Tian X; Wang Y
    J Cancer Res Clin Oncol; 2024 Jul; 150(7):340. PubMed ID: 38976071
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of PD-1 inhibitors on prognosis in unresectable hepatocellular carcinoma treated with TACE and lenvatinib: a retrospective study.
    Ding Z; Fang G; Tang Y; Zeng Y
    Sci Rep; 2024 Jun; 14(1):14334. PubMed ID: 38906915
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.